Related Experiment Video
Updated: Jul 1, 2025
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Novel Titanocene Y derivative with albumin affinity exhibits improved anticancer activity against platinum resistant
Sergio Gomez-Lopez1, Rosario Serrano2, Boiko Cohen3
1Facultad de Ciencias Ambientales y Bioquímica, Universidad de Castilla-La Mancha, 45071 Toledo, Spain.
Abstract:
The antitumor activity of Ti(IV)-based compounds put them in the spotlight for cancer treatment in the past, but their lack of stability in vivo due to a high rate of hydrolysis has hindered their development as antitumor drugs. As a possible solution for this problem, we have reported a synthesis strategy through which we combined a titanocene fragment, a tridentate ligand, and a long aliphatic chain. This strategy allowed us to generate a titanium compound (Myr-Ti) capable of interacting with albumin, highly stable in water and with cytotoxic activity in tumor cells[1]. Following a similar strategy, now we report the synthesis of a new compound (Myr-TiY) derived from titanocene Y that shows antitumoral activity in a cisplatin resistant model with a 50% inhibitory concentration (IC50) of 41-76 μM. This new compound shows high stability and a strong interaction with human serum albumin. Myr-TiY has a significant antiproliferative and proapoptotic effect on the tested cancer cells and shows potential tumor selectivity when assayed in non-tumor human epithelial cells being more selective (1.3-3.8 times) for tumor cells than cisplatin. These results lead us to think that the described synthesis strategy could be useful to generate compounds for the treatment of both cisplatin-sensitive and cisplatin-resistant cancers.
Insights
Researchers developed a stable titanium compound (Myr-TiY) with significant antitumor activity against cisplatin-resistant cancer cells. This compound demonstrates tumor selectivity and offers a promising strategy for developing novel cancer therapeutics.
Area of Science:
- Medicinal Chemistry
- Oncology
- Materials Science
Background:
- Titanium(IV)-based compounds show antitumor potential but suffer from poor in vivo stability due to hydrolysis.
- Previous work introduced a stable titanocene-albumin-binding compound (Myr-Ti) using a specific synthesis strategy.
Purpose of the Study:
- To synthesize and evaluate a novel titanium compound (Myr-TiY) derived from titanocene Y.
- To assess its efficacy against cisplatin-resistant cancer models and its tumor selectivity.
Main Methods:
- Synthesis of Myr-TiY by combining a titanocene Y fragment, a tridentate ligand, and a long aliphatic chain.
- Evaluation of antitumoral activity, in vitro stability, albumin interaction, antiproliferative, and proapoptotic effects.
- Assay of tumor selectivity in non-tumor human epithelial cells compared to cisplatin.
Main Results:
- Myr-TiY exhibits antitumoral activity in a cisplatin-resistant model with an IC50 of 41-76 μM.
- The compound demonstrates high stability in water and strong interaction with human serum albumin.
- Myr-TiY shows significant antiproliferative and proapoptotic effects and is 1.3-3.8 times more selective for tumor cells than cisplatin.
Conclusions:
- The developed synthesis strategy yields stable titanium compounds with potent antitumor activity.
- Myr-TiY shows promise for treating both cisplatin-sensitive and cisplatin-resistant cancers.
- The compound's tumor selectivity suggests a favorable therapeutic profile.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers